Last reviewed · How we verify

Glimepiride or gliclazide — Competitive Intelligence Brief

Glimepiride or gliclazide (Glimepiride or gliclazide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea. Area: Diabetes.

phase 3 Sulfonylurea ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glimepiride or gliclazide (Glimepiride or gliclazide) — Merck Sharp & Dohme LLC. Glimepiride and gliclazide stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Glimepiride or gliclazide TARGET Glimepiride or gliclazide Merck Sharp & Dohme LLC phase 3 Sulfonylurea ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor
Amaryl GLIMEPIRIDE Sanofi marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1995-01-01
Glucotrol GLIPIZIDE Pfizer marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1984-01-01
Micronase glibenclamide Sanofi marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1984-01-01
Aglicid TOLBUTAMIDE marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1961-01-01
Diabinese CHLORPROPAMIDE Pfizer marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1958-01-01
Glimepiride/metformin fixed combination Glimepiride/metformin fixed combination Handok Inc. marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea class)

  1. Merck Sharp & Dohme LLC · 6 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Sanofi · 2 drugs in this class
  4. Janssen Research & Development, LLC · 1 drug in this class
  5. Samsung Medical Center · 1 drug in this class
  6. Servier Affaires Médicales · 1 drug in this class
  7. The George Institute · 1 drug in this class
  8. · 1 drug in this class
  9. University of Glasgow · 1 drug in this class
  10. GRADE Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glimepiride or gliclazide — Competitive Intelligence Brief. https://druglandscape.com/ci/glimepiride-or-gliclazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: